REGN: Regeneron Corp Price to Net Income Growth Ratio

Symbol and logo of brand Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN) holds undisputed authority in biotechnology due to the creation of innovative treatments for heart and vision conditions. Historical PEG ratio dynamics demonstrate the market valuation of the asset, where the 0.69 level represents the current value. The company's prospects are based on the success of the drug Dupixent and new oncology developments. Business efficiency is supported by the strategic allocation of clinical trials between in-house staff and external laboratories.

REGN Regeneron Corp Price/Earnings to Growth Ratio (07/04/2022 - 11/16/2026)

Metric breakdowns and analytics for Regeneron (REGN)

- current quotes and average value forecast:
Fundamental company analysis:REGN - Regeneron Corp
Mass-produced product of regeneron.com

This metric compares the market value of the share with net income dynamics, allowing for the determination of the asset's fair value through the lens of its expansion. For Regeneron Pharmaceuticals (REGN), whose VelociSuite platform accelerates antibody creation, this analysis reveals an undervaluation of innovative potential if the growth-weighted P/E falls below one, signaling a high probability of outperformance.